Back

Factor Xa inhibitor associated major bleeding characteristics, burden, and health resource utilization in Alberta, Canada - an observational population based study

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Unmet needs in anticoagulant pharmacotherapy Anticoagulants ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Professor Robert Welsh

Mazankowski Alberta Heart Institute, Edmonton (Canada)

7 More presentations in this session

Presentation thumbnail
Clinical impact of kidney function in patients with atrial fibrillation receiving oral anticoagulants
Doctor Y. Matsuoka (Osaka, JP)
Abstract Slides Video
Presentation thumbnail
Navigating optimal antithrombotic therapy in atrial fibrillation patients with PCI: insights from the EPIC-CAD trial
Doctor S. Wee (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Plasma levels measurement of the four direct oral anticoagulants in patients with atrial fibrillation at the time of acute thromboembolic and bleeding events
Doctor R. Mazza (Milan, IT)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of direct oral anticoagulants for treatment of left ventricular thrombus
Doctor K. Abraham (Stony Brook, US)
Abstract Slides Video
Presentation thumbnail
Direct oral anticoagulants versus warfarin for left ventricular thrombus
Doctor J. Kassab (Dallas, US)
Abstract Slides Video

Access the full session

Session thumbnail
Unmet needs in anticoagulant pharmacotherapy

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
The incidence of death and risk factors for mortality following major bleeding in patients anticoagulated with factor Xa inhibitors: an observational study in the UK clinical setting (AXIOM UK)
thumbnail
Congress Presentation
Association between warfarin and direct oral anticoagulants users and risk of mortality: cohort studies in England and Hong Kong
thumbnail
Congress Presentation
Impact of resumption of Oral AntiCoagulation therapy (OAC) after GastroIntestinal Bleeding (GIB) on clinical outcomes in patients with Non-Valvular Atrial Fibrillation (NVAF)

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources